Correction: Cost‑effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands
Sara W. Quist, Alexander V. van Schoonhoven, Stephan J. L. Bakker, Michał Pochopień, Maarten J. Postma, Jeanni M. T. van Loon, Jeroen H. J. Paulissen
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsDiabetes Treatment and Management · Pharmacology and Obesity Treatment · Diet and metabolism studies
Correction to: Cardiovascular Diabetology (2023) 22:328 10.1186/s12933-023-02053-6
In the original publication of this article [1], the authors identified typographical errors in Tables 2 and 7. In Table 2, the transition probability from CKD1/2 to CKD4 should be “0.0036” instead of “0.36”. In Table 7, the total indirect costs “€111,706 and €12,4069” was incorrect and should have been “€11,706 and €12,406”, though the difference between the two values remains correct. These corrections do not affect the methodology, results, or conclusion section.
Table 2. Transition probabilities: CKD progression and first modelled CV event and OHE probabilities [13]CKD1/2CKD3CKD4CKD5 w/o dialysisDialysis (acute)Dialysis (post-acute)Kidney Transplant (acute)Kidney Transplant (post-acute)Transition probabilities CKD progression for patients receiving SoC^a^ [13]CKD1/20.66960.32680.0036CKD30.03500.87050.09310.00110.0002CKD40.00120.14000.80430.04480.0096CKD 5 w/o dialysis0.01350.08890.71430.17790.0054Dialysis (acute)1.0000Dialysis (post-acute)0.99210.0079Kidney transplant (acute)1.0000Kidney transplant (post-acute)1.0000CKD1/2CKD3CKD4CKD5 w/o dialysisDialysis (acute)Dialysis (post-acute)Kidney Transplant (acute)Kidney Transplant (post-acute)Transition probabilities CKD progression for patients receiving SoC and Finerenone^a^ [13]CKD1/20.63050.36650.0030CKD30.02690.87700.09490.00090.0002CKD40.00160.15480.79820.03710.0083CKD 5 w/o dialysis0.00750.12670.70450.15590.0054Dialysis (acute)1.0000Dialysis (post-acute)0.99210.0079Kidney transplant (acute)1.0000Kidney transplant (post-acute)1.0000CKD1/2CKD3CKD4CKD5 w/o dialysisDialysis (acute)Dialysis (post-acute)Kidney Transplant (acute)Kidney Transplant (post-acute)Transition probabilities for CV events per CKD stage [13]Any CV event probability^b^0.01190.01270.01570.02080.02080.02080.01570.0157CV death0.00620.00520.00810.01570.01910.01910.00810.0081Renal death0.0000.0000.0000.00010.0000.0000.0000.000Probabilities of OHEs [13] No CV events
CV event Subsequent CV event–7.32%Hyperkalaemia leading to hospitalization0.07%0.38%Hyperkalaemia not leading to hospitalization1.63%2.35%New onset of atrial fibrillation0.35%2.16%CKD chronic kidney disease, CV cardiovascular, eGFR estimated glomerular filtration rate, HR hazard ratio, MI Myocardial infarction, OHE Other health events, SoC standard of care, w/o without^a^ The transition probabilities of CKD progression were based on end points that were measured every four months in the FIDELIO-DKD trial with a median follow-up of 2.6 years. For patients that received finerenone, the probability of transitioning to CKD 5 was adjusted with the HR for the onset of eGFR decrease < 15 mL/min/1.73 m^2^ sustained over at least four weeks, and the probability of transition to dialysis was adjusted with the HR for progression to dialysis.^b^ CV events included non-fatal MI, stroke, or hospitalization for heart failure
Table 7. Costs, QALYs, and ICER per patient over a lifetime for finerenone + SoC and SoCFinerenone + SoCSoCDifferenceCosts within the healthcare system Medication costs€10,098€6,554€3,545 CKD treatment€4272€4,125€148 Dialysis€57,650€65,584− €7,935 Transplant€2262€2,125− €275 First CV event costs€5843€6,134− €291 Subsequent CV event€1528€1,633− €105 Hyperkalaemia leading to hospitalization€159€88€70 Hyperkalaemia not leading to hospitalization€192€126€66 New onset of atrial fibrillation€168€198− €30Indirect costs for patients and caregivers€11,076€12,406− €1,329Total costs (healthcare perspective)€82,172€86,978− €4,708Total costs (societal perspective)€93,248€99,384− €6,136Total effects (life-years without CV)7.437.130.30Total effects (life-years without RRT)8.658.340.31Total effects (life-years)9.409.180.22Total effects (QALY)7.056.850.20ICER (costs/QALY)Finerenone + SoC is a dominant treatment optionCKD chronic kidney disease,* CV* cardiovascular,* eGFR* estimated glomerular filtration rate,* ICER* incremental cost-effectiveness ratio,* MI* myocardial infarction,* QALY* quality-adjusted life year,* RRT* renal replacement therapy,* SoC* standard of care